Lipopolysaccharide Receptors

Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including MONOCYTES; MACROPHAGES; and some GRANULOCYTES. They function as receptors for the complex of lipopolysaccharide (LPS) and LPS-binding protein.

Also Known As:

CD14 Antigen; CD14 Monocyte Differentiation Antigen; LPS Receptor; Lipoglycan Receptor; Receptor, LPS; Receptor, Lipoglycan; CD14 Antigen, Soluble; CD14 Protein, Soluble; CD14, Soluble; Antigens, CD14; CD14 Antigens; Receptors, Lipopolysaccharide; Soluble CD14; Soluble CD14 Antigen; Soluble CD14 Protein; sCD14

Networked: 889 relevant articles (19 outcomes, 136 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Trøseid, Marius: 13 articles (05/2022 - 12/2014)
2.	Landay, Alan L: 12 articles (01/2022 - 09/2012)
3.	Tracy, Russell P: 12 articles (01/2021 - 01/2013)
4.	Lederman, Michael M: 11 articles (01/2021 - 09/2012)
5.	McComsey, Grace A: 8 articles (12/2021 - 04/2014)
6.	Sereti, Irini: 8 articles (01/2020 - 03/2011)
7.	Morgello, Susan: 8 articles (01/2019 - 08/2011)
8.	Margolick, Joseph B: 8 articles (01/2018 - 04/2009)
9.	Deeks, Steven G: 8 articles (12/2016 - 03/2011)
10.	Paape, Max J: 8 articles (07/2006 - 05/2002)

Related Diseases

1.	Inflammation (Inflammations) 01/01/2017 - "In a sub-study of these patients, we observed significantly higher parameters of microbial translocation (LBP, soluble CD14) and systemic inflammation in immunologic non-responders than in immunologic responders, which was correlated with a relative abundance of specific gut bacterial groups (Lachnospiraceae genus and Proteobacteria). " 01/01/2017 - "Several inflammation markers significantly decreased in all study arms; soluble CD14 increased on ABC and did not change in the other 2 arms. " 07/01/2003 - "One quarter of six healthy lactating cows was challenged with 100 microg LPS in order to study the kinetics of sCD14 during an LPS-induced inflammation. " 11/01/2002 - "The purpose of this study was to determine whether microbial invasion of the amniotic cavity (MIAC)/intra-amniotic inflammation (both preterm and term) and parturition at term are associated with changes in the amniotic fluid and umbilical plasma soluble concentrations of CD14 (sCD14). " 11/28/2022 - "Intestinal FABP correlated with ZO-1 (ρ = 0.11, P = .014), sCD14 (ρ = 0.12, P = .0046) as well as markers of inflammation and endothelial activation. "
2.	Endotoxemia 02/01/2018 - "Moreover, an increase in the expression of the LPS receptor led to higher concentrations of plasma HDL and lower serum Ca, which may be a protective mechanism against endotoxemia. " 07/01/2014 - "Overfeeding increases postprandial endotoxemia in men: Inflammatory outcome may depend on LPS transporters LBP and sCD14." 10/01/2002 - "The elevation in LBP and sCD14 levels may be a consequence of endotoxemia." 02/01/2002 - "Liver might be a main source for soluble CD14 production during endotoxemia." 11/01/2001 - "The diagnostic accuracy of endotoxemia obtained by ES, mCD14, MFI-CD14 and sCD14 were 77.3%, 95.5%, 86.7% and 66.7%, respectively, so that the highest was given by the positive mCD14 cell rate. "
3.	Septic Shock (Toxic Shock Syndrome) 11/01/2006 - "Recent research has produced contradictory observations suggesting that sCD14 may have either beneficial or detrimental properties in protection against LPS-induced endotoxin shock. " 06/15/1994 - "To assess the utility of soluble forms of the CD14 receptor as a possible therapeutic for endotoxin shock, we have produced recombinant human soluble CD14 using a baculovirus expression system. " 05/01/2006 - "Therefore, these data indicate the possibility that the sCD14 level did not increase consistently, even under a fatal condition in endotoxin shock. " 11/01/2003 - "In addition, recent therapeutic approaches for septic shock targeting the LPS receptor complex are described." 07/01/2002 - "The most recent advances in the understanding of the function of the LPS receptor complex and its role in the development of the septic shock syndrome and endotoxin tolerance will be discussed."
4.	Shock 01/01/1998 - "The application of its soluble form, sCD14, has been shown to protect mice from lethality in LPS-induced shock. " 01/01/1992 - "Therefore, sCD14 may be a new therapeutic concept in endotoxic shock prevention." 06/15/1995 - "These results suggest that the soluble CD14 receptor may represent a new form of therapy for endotoxic shock in humans." 07/01/2006 - "Binding of the soluble form of CD14 (sCD14) to LPS, found in the outer membrane of Escherichia coli and other Gram-negative bacteria, enhances host innate immune responses, reduces the severity of mastitis, and facilitates clearance and neutralization of LPS, thus protecting against an excessive immune response to LPS and development of endotoxic shock. " 03/01/1998 - "However, application of sCD14 had no effect on the secretion of early proinflammatory cytokines and did not protect the animals against the development of apparent shock symptoms and liver injury. "
5.	Autoimmune Diseases (Autoimmune Disease) 10/01/2001 - "Receiver operating characteristic curve analysis suggested a reasonable diagnostic efficacy of sCD14 quantification in this autoimmune disease. " 01/01/1994 - "Antagonism in signaling between the antigen and LPS receptor is not a general B cell hyporesponsiveness, but defects in antagonism specifically between antigen and LPS signaling may be a predisposing factor to autoimmune disease in some autoimmune strains of mice." 07/01/2021 - "Currently, drugs targeting the TLR4 signaling pathway mainly act on LPS and its receptor LPS binding protein (LBP), CD14, myeloid differentiation protein 2 (MD2), and TLR4, such as lipid A analogs and natural products as well as their derivatives, and natural and synthetic peptides and proteins, etc. They have potential therapeutic effects in the treatment of autoimmune diseases, acute and chronic inflammation, cardiovascular diseases, and neurological diseases."

Related Drugs and Biologics

1.	Lipopolysaccharide Receptors
2.	Proteins (Proteins, Gene)
3.	Lipopolysaccharides
4.	Lipid A
5.	Biomarkers (Surrogate Marker)
6.	Interleukin-6 (Interleukin 6)
7.	Cytokines
8.	zonulin
9.	Ribosomal DNA (rDNA)
10.	Interleukin-4 (Interleukin 4)

Related Therapies and Procedures

1.	Therapeutics
2.	Art Therapy
3.	Spinal Injections
4.	Renal Dialysis (Hemodialysis)
5.	Highly Active Antiretroviral Therapy (HAART)